Jefferies analyst Thomas Wei reiterated a Buy rating and $197 price target on Celgene (NASDAQ: CELG) saying the Revlimid markman ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE